NEW YORK (GenomeWeb News) — BG Medicine said yesterday that it has withdrawn its registration statement with the US Securities and Exchange Commission for an initial public offering.
The Waltham, Mass.-based biomarker and molecular diagnostics maker cited “current market conditions” for its decision not to proceed with the IPO. It did not elaborate on those conditions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.